ADA_ETA_BIO2021: real-world evaluation of adherence, persistence, and cost-effectiveness of originator and biosimilar biologic drugs in the treatment of rheumatoid arthritis: a multicenter study in Italy.

MLA

Santoleri, Fiorenzo, et al. “ADA_ETA_BIO2021: Real-World Evaluation of Adherence, Persistence, and Cost-Effectiveness of Originator and Biosimilar Biologic Drugs in the Treatment of Rheumatoid Arthritis: A Multicenter Study in Italy.” Current Medical Research and Opinion, vol. 39, no. 12, Dec. 2023, pp. 1729–35. EBSCOhost, https://doi.org/10.1080/03007995.2023.2287600.

APA

Santoleri, F., Lasala, R., Abrate, P., Pestrin, L., Pasut, E., Modesti, G., Musicco, F., Fulgenzio, C., Zuzolo, E., Pieri, G., Roperti, M., Gazzola, P., Gambera, M., Martignoni, I., Montresor, V., De Vita, F., Guarino, F., Grossi, L., Di Fabio, L., … Costantini, A. (2023). ADA_ETA_BIO2021: real-world evaluation of adherence, persistence, and cost-effectiveness of originator and biosimilar biologic drugs in the treatment of rheumatoid arthritis: a multicenter study in Italy. Current Medical Research and Opinion, 39(12), 1729–1735. https://doi.org/10.1080/03007995.2023.2287600

Chicago

Santoleri, Fiorenzo, Ruggero Lasala, Paolo Abrate, Laura Pestrin, Enrico Pasut, Germana Modesti, Felice Musicco, et al. 2023. “ADA_ETA_BIO2021: Real-World Evaluation of Adherence, Persistence, and Cost-Effectiveness of Originator and Biosimilar Biologic Drugs in the Treatment of Rheumatoid Arthritis: A Multicenter Study in Italy.” Current Medical Research and Opinion 39 (12): 1729–35. doi:10.1080/03007995.2023.2287600.